PreprintCited by 28PI3K/AKT/mTOR signaling in cancerProtein Kinase Regulation and GTPase SignalingCellular transport and secretion

The DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.

Molecular basis for differential activation of p101 and p84 complexes of PI3Kγ by Ras and GPCRs

Open access

Preprint — published as 10.1016/j.celrep.2023.112172 · Paper page

Abstract

Class IB phosphoinositide 3-kinase (PI3Kγ) is activated in immune cells by diverse stimuli and can form two distinct complexes, with the p110γ catalytic subunit binding to either p101 or p84 regulatory subunits. These two complexes are differentially activated by G-protein coupled receptors (GPCRs) and Ras, but the molecular details of this activation are still unclear. Using a combination of X-ray crystallography, HDX-MS, EM, molecular modeling, and biochemical assays we reveal molecular differences between the two p110γ-p84 and p110γ-p101 complexes that explain their differential activation. The structure of p110γ-p84 shows a similar assembly to p110γ-p101 at the p110γ interface, however the interface in p110γ-p84 is dynamic and is evolutionarily conserved to be less stable compared to p110γ-p101. The p110γ-p84 complex is only weakly recruited to membranes by Gβγ subunits alone and requires recruitment by Ras to allow for Gβγ activation through an interaction with the p110γ helical domain. The interfaces of the p101 GBD with Gβγ, and the p110γ helical domain with Gβγ were determined using computational alphafold2 modeling and HDX-MS. There are distinct differences in the C-terminal domain of p84 and p101, which allows p101 to bind Gβγ subunits, while p84 does not. The two Gβγ interfaces in p110γ and p101 are distinct, revealing how unique mutants of Gβγ cause differential disruption of PI3Kγ complex activation. Overall, our work provides key insight into the molecular basis for how different PI3Kγ complexes are activated.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1101/2022.07.29.502076

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. 10.1038/s41577-022-00701-8 · DOI
  2. 10.1016/S0092-8674(00)80187-7 · DOI
  3. 10.1016/j.cub.2005.02.020 · DOI
  4. 10.1074/jbc.M512502200 · DOI
  5. 10.1126/science.287.5455.1046 · DOI
  6. 10.1016/S1074-7613(02)00282-0 · DOI
  7. 10.1126/science.287.5455.1049 · DOI
  8. B. Nürnberg , S. Beer-Hammer , Function, Regulation and Biological Roles of PI3Kγ Variants. Biomolecules. 9, E427 (2019). · DOI
  9. 2005, PI3Kgamma inhibition blocks glomerulonephritis and extends lifespan in a mouse model of systemic lupus, Nat. Med, 11, 933, 10.1038/nm1291 · DOI
  10. 10.1038/nm1284 · DOI
  11. 10.1161/CIRCULATIONAHA.107.720466 · DOI
  12. 2018, Inhalation of the prodrug PI3K inhibitor CL27c improves lung function in asthma and fibrosis, Nat Commun, 9, 5232, 10.1038/s41467-018-07698-6 · DOI
  13. 10.1073/pnas.1106698108 · DOI
  14. 10.1126/scisignal.aaf2969 · DOI
  15. 10.1073/pnas.1813012116 · DOI
  16. 10.1158/0008-5472.CAN-14-3303 · DOI
  17. 10.1038/nature19834 · DOI
  18. 10.1038/nature20554 · DOI
  19. 2021, Targeting PI3K/AKT/mTOR Signaling Pathway in Breast Cancer, Cancers (Basel, 13, 3517, 10.3390/cancers13143517 · DOI
  20. 10.1038/s41467-019-12311-5 · DOI
  21. 10.3324/haematol.2019.231399 · DOI
  22. 10.1126/science.7624799 · DOI
  23. 10.1016/j.ccr.2011.04.016 · DOI · Paper page
  24. 10.1038/ncomms5407 · DOI
  25. 10.1126/scisignal.2005564 · DOI
  26. 10.1126/scisignal.aaz4003 · DOI
  27. 10.1126/scisignal.2000259 · DOI
  28. 10.1073/pnas.1304801110 · DOI
  29. 10.1074/jbc.274.41.29311 · DOI
  30. 10.1126/sciadv.abj4282 · DOI
  31. 10.1074/jbc.M113.508234 · DOI
  32. 10.1073/pnas.0905506106 · DOI
  33. 10.1038/46319 · DOI
  34. M. K. Rathinaswamy , Z. Gaieb , K. D. Fleming , C. Borsari , N. J. Harris , B. E. Moeller , M. P. Wymann , R. E. Amaro , J. E. Burke , Disease-related mutations in PI3Kγ disrupt regulatory C-terminal dynamics and reveal a path to selective inhibitors. Elife. 10, e64691 (2021). · DOI
  35. 10.1016/S0092-8674(00)00196-3 · DOI
  36. 10.1042/BJ20111664 · DOI
  37. 10.1101/2021.10.04.463034 · DOI · Paper page
  38. 2019, A class of highly selective inhibitors bind to an active state of PI3Kγ, Nature Chemical Biology, 15, 348, 10.1038/s41589-018-0215-0 · DOI
  39. 10.1126/science.1082348 · DOI
  40. 10.1146/annurev-immunol-032712-095946 · DOI · Paper page
  41. 10.1042/BJ20150099 · DOI
  42. 10.1371/journal.pbio.1001587 · DOI
  43. J. R. Jin , E. Gogvadze , A. R. Xavier , T. Bohnacker , J. Voelzmann , M. P. Wymann , PI3Kγ Regulatory Protein p84 Determines Mast Cell Sensitivity to Ras Inhibition-Moving Towards Cell Specific PI3K Targeting? Front Immunol. 11, 585070 (2020). · DOI
  44. 10.1016/j.str.2011.06.003 · DOI
  45. 10.1073/pnas.1205508109 · DOI · Paper page
  46. 10.1128/MCB.18.3.1379 · DOI
  47. 10.1083/jcb.200210115 · DOI
  48. 10.1126/scisignal.2003264 · DOI
  49. 2021, HDX-MS-optimized approach to characterize nanobodies as tools for biochemical and structural studies of class IB phosphoinositide 3-kinases, Structure, 29, 1371, 10.1016/j.str.2021.07.002 · DOI
  50. 2021, Regulation and metabolic functions of mTORC1 and mTORC2, Physiological Reviews, 101, 1371, 10.1152/physrev.00026.2020 · DOI
  51. 10.1074/jbc.M117.789263 · DOI
  52. 2004, Purification of G protein subunits from Sf9 insect cells using hexahistidine-tagged alpha and beta gamma subunits, Methods Mol. Biol, 237, 21
  53. 2022, ColabFold: making protein folding accessible to all, Nat Methods, 19, 679, 10.1038/s41592-022-01488-1 · DOI · Paper page
  54. F. Gorrec , J. Löwe , Automated Protocols for Macromolecular Crystallization at the MRC Laboratory of Molecular Biology. JoVE, 55790 (2018). · DOI
  55. 10.1016/j.pbiomolbio.2004.07.009 · DOI
  56. 10.1107/S0021889809042022 · DOI
  57. 10.1038/nprot.2017.037 · DOI
  58. 10.1107/S0907444905036693 · DOI
  59. 10.1107/S0021889807021206 · DOI · Paper page
  60. 10.1107/S0907444912001308 · DOI · Paper page
  61. 10.1107/S0907444910007493 · DOI · Paper page
  62. 10.1021/jasms.0c00283 · DOI
  63. 10.1038/s41592-019-0459-y · DOI
  64. 2022, The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences, Nucleic Acids Res, 50, D543, 10.1093/nar/gkab1038 · DOI · Paper page
  65. 10.1093/NAR/GKAB1061 · DOI · Paper page

Metadata

Authors
Rathinaswamy, M. K., Jenkins, M. L., Zhang, X., Stariha, J. T., Ranga-Prasad, H., Dalwadi, U., Fleming, K. D., Yip, C. K., Williams, R. L., & Burke, J. E.
Affiliations
  • University of Victoria (CA)
  • MRC Laboratory of Molecular Biology (GB)
  • University of British Columbia (CA)
Corresponding author
Burke, John E
Venue
Cell Reports
Publisher
openRxiv
Published
2022-07-30
Volume
42
Issue
3
Pages
112172-112172
ISSN
2211-1247 (ISSN-L)
OpenAlex
W4322154690
Cited by
28
References
1
Citations by year
2026: 5 · 2025: 4 · 2024: 4 · 2023: 15
FWCI
2.48
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Cell Reports (publishedVersion, cc-by-nc-nd)
  • bioRxiv (Cold Spring Harbor Laboratory) (acceptedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
  • UVic’s Research and Learning Repository (University of Victoria) (submittedVersion, cc-by-nc-nd)
Funders
  • National Science Foundation (2048060)
  • Novartis Pharmaceuticals Corporation
  • Michael Smith Health Research BC (MSFHR-17686, FDN-143228, 17686)
  • Cancer Research UK (DRCPGM\\100014)
  • European Synchrotron Radiation Facility
  • Cambridge Overseas Trust
  • National Institutes of Health (FDN-143228)
  • Canadian Institutes of Health Research (168998, 143228_1)
  • Natural Sciences and Engineering Research Council of Canada (rgpin-2018-03951)
  • Medical Research Council (MC_U105184308)
  • National Institute of General Medical Sciences (T32GM007759)
Topics
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
Keywords
PI3Kγ, p110γ, P84, G protein-coupled receptors, Ras, Gβγ subunits, membrane recruitment, enzyme activation, immune cells, phosphatidylinositol 3-kinase, protein complex dynamics
MeSH terms
Models, Molecular, Signal Transduction, Phosphatidylinositol 3-Kinases, Receptors, G-Protein-Coupled, Phosphatidylinositol 3-Kinase

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review